retatrutide
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors. In clinical trials, it produced unprecedented weight loss results, making it potentially the most effective obesity treatment developed.
Lab Notes — Research Studies
01 Retatrutide, A Trigonal Glp-1, Gip And Glucagon Receptor Agonist, And Its Role In Weight Reduction
Study found retatrutide significantly reduces weight, waist circumference, and BMI in overweight adults while improving cardiometabolic parameters.
View Study ((ScienceDirect))02 Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomized, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
Retatrutide significantly improved blood sugar control and reduced body weight across various doses, demonstrating higher effectiveness than placebo and dulaglutide.
View Study ((ScienceDirect))03 The Effect Of Triple-Hormone-Receptor Agonist Retatrutide, A Novel Medication For Weight Loss, On Blood Pressure
Retatrutide showed potential to significantly lower both systolic and diastolic blood pressure based on phase 2 trials.
View Study ((ScienceDirect))04 Retatrutide showing promise in obesity (and type 2 diabetes)
Retatrutide led to significant weight loss over 24 weeks but frequently caused gastrointestinal side effects.
View Study ((PubMed))05 A review of an investigational drug Retatrutide, a novel triple agonist agent for the treatment of obesity
Retatrutide, in Phase III trials, has shown promising weight loss results in earlier trials, indicating potential for treating obesity.
View Study ((PubMed))Formula — Benefits & Dosage
⚗️ Effects
- Most Effective Weight Loss: Highest recorded in clinical trials.
- Dose-Dependent: Higher doses produce greater weight loss.
- Under Development: Still in clinical trials.
💉 Dosage & Administration
- Clinical Trial Doses: 1-12mg weekly in phase 2 trials.
- Weekly Injection: Administered once weekly.
- Dose Titration: Started low and increased gradually.
⚠️ Side Effects
- GI Effects: Nausea, vomiting, diarrhea common.
- Similar to GLP-1s: Side effect profile comparable to semaglutide.
- Dose-Related: Higher doses mean more side effects.
- Generally Manageable: Most side effects decrease over time.
📦 Availability & Sourcing
- Not Yet Approved: Still in phase 3 clinical trials.
- Research Chemical: Available from some peptide suppliers.
- Future Availability: Expected FDA review pending trial completion.
Reaction Log — User Experiences
Early adopters report dramatic weight loss exceeding semaglutide results. Side effects similar to other GLP-1 agonists. Not yet FDA approved but generating significant interest.
Synthesis — Related Compounds
⚠️ IMPORTANT DISCLAIMER
This information is for educational and research purposes only. retatrutide may not be approved for human use. Always consult a qualified healthcare professional before using any supplements or research compounds. We do not guarantee accuracy or completeness of information presented.